Molecular and Epigenetic Aspects of Opioid Receptors in Drug Addiction and Pain Management in Sport

Opioids are substances derived from opium (natural opioids). In its raw state, opium is a gummy latex extracted from Papaver somniferum. The use of opioids and their negative health consequences among people who use drugs have been studied. Today, opioids are still the most commonly used and effective analgesic treatments for severe pain, but their use and abuse causes detrimental side effects for health, including addiction, thus impacting the user’s quality of life and causing overdose. The mesocorticolimbic dopaminergic circuitry represents the brain circuit mediating both natural rewards and the rewarding aspects of nearly all drugs of abuse, including opioids. Hence, understanding how opioids affect the function of dopaminergic circuitry may be useful for better knowledge of the process and to develop effective therapeutic strategies in addiction. The aim of this review was to summarize the main features of opioids and opioid receptors and focus on the molecular and upcoming epigenetic mechanisms leading to opioid addiction. Since synthetic opioids can be effective for pain management, their ability to induce addiction in athletes, with the risk of incurring doping, is also discussed.

[1]  B. Roth,et al.  Structures of the entire human opioid receptor family , 2023, Cell.

[2]  Handong Ouyang,et al.  CircNf1-mediated CXCL12 expression in the spinal cord contributes to morphine analgesic tolerance , 2022, Brain, Behavior, and Immunity.

[3]  N. Mercuri,et al.  Morpho‐Functional Changes of Nigral Dopamine Neurons in an α‐Synuclein Model of Parkinson's Disease , 2022, Movement disorders : official journal of the Movement Disorder Society.

[4]  A. Viggiano,et al.  Neuroinflammation: molecular mechanisms and therapeutic perspectives. , 2022, Central nervous system agents in medicinal chemistry.

[5]  T. Robbins,et al.  Multi-omics study reveals associations among neurotransmitter, extracellular vesicle-derived microRNA and psychiatric comorbidities during heroin and methamphetamine withdrawal. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  Jingwei Tian,et al.  MicroRNAs in drug addiction: Current status and future perspectives. , 2022, Pharmacology & therapeutics.

[7]  Ling-Ling Chen,et al.  Circular RNAs: Characterization, cellular roles, and applications , 2022, Cell.

[8]  X. Li,et al.  CircTmeff-1 in the nucleus accumbens regulates the reconsolidation of cocaine-associated memory , 2022, Brain Research Bulletin.

[9]  I. Pronina,et al.  Circulating MicroRNAs as a New Class of Biomarkers of Physiological Reactions of the Organism to the Intake of Dietary Supplements and Drugs. , 2022, MicroRNA.

[10]  N. Mercuri,et al.  Pathophysiological Features of Nigral Dopaminergic Neurons in Animal Models of Parkinson’s Disease , 2022, International journal of molecular sciences.

[11]  M. Wimmer,et al.  microRNA expression levels in the nucleus accumbens correlate with morphine‐taking but not morphine‐seeking behaviour in male rats , 2022, The European journal of neuroscience.

[12]  H. Pan,et al.  Epigenetic Mechanisms of Neural Plasticity in Chronic Neuropathic Pain. , 2022, ACS chemical neuroscience.

[13]  K. Dąbrowski,et al.  Heroin Regulates Orbitofrontal Circular RNAs , 2022, International journal of molecular sciences.

[14]  Hailei Yu,et al.  Roles of miR-592-3p and Its Target Gene, TMEFF1, in the Nucleus Accumbens During Incubation of Morphine Craving , 2022, The international journal of neuropsychopharmacology.

[15]  Y. Olsen What Is Addiction? History, Terminology, and Core Concepts. , 2022, The Medical clinics of North America.

[16]  Rajesh Raju,et al.  Opioid receptors signaling network , 2021, Journal of Cell Communication and Signaling.

[17]  Lieliang Zhang,et al.  Long Non-coding RNAs and Circular RNAs: Insights Into Microglia and Astrocyte Mediated Neurological Diseases , 2021, Frontiers in Molecular Neuroscience.

[18]  Cailian Cui,et al.  MicroRNA‐132 is involved in morphine dependence via modifying the structural plasticity of the dentate gyrus neurons in rats , 2021, Addiction biology.

[19]  S. Bradburn,et al.  Differential expression of H19, BC1, MIAT1, and MALAT1 long non-coding RNAs within key brain reward regions after repeated morphine treatment , 2021, Behavioural Brain Research.

[20]  E. Sohn Treatment of neuropathic pain , 2021, Journal of the Korean Medical Association.

[21]  K. Iczkowski,et al.  Peripheral antinociceptive effects of a bifunctional μ and δ opioid receptor ligand in rat model of inflammatory bladder pain , 2021, Neuropharmacology.

[22]  P. Vivekanandan,et al.  Biogenesis, characterization, and functions of mirtrons , 2021, Wiley interdisciplinary reviews. RNA.

[23]  T. Zandonai,et al.  Codeine and Tramadol Use in Athletes: A Potential for Abuse , 2021, Frontiers in Pharmacology.

[24]  B. Cong,et al.  The role of circTmeff-1 in incubation of context-induced morphine craving. , 2021, Pharmacological research.

[25]  D. Fischer,et al.  CXCR4/CXCL12-mediated entrapment of axons at the injury site compromises optic nerve regeneration , 2021, Proceedings of the National Academy of Sciences.

[26]  J. Cadet,et al.  Epigenetics of addiction , 2021, Neurochemistry International.

[27]  B. Tai,et al.  The NIDA clinical trials network: evolving, expanding, and addressing the opioid epidemic , 2021, Addiction Science & Clinical Practice.

[28]  C. Mortali,et al.  Opioid epidemic spread from Northern and Eastern Europe to Mediterranean Area. , 2021, La Clinica terapeutica.

[29]  M. Lai,et al.  Role of nucleus accumbens microRNA-181a and MeCP2 in incubation of heroin craving in male rats , 2021, Psychopharmacology.

[30]  Yusheng Yao,et al.  Efficacy of systemic lidocaine on postoperative quality of recovery and analgesia after video-assisted thoracic surgery: A randomized controlled trial. , 2021, Journal of clinical anesthesia.

[31]  H. Loh,et al.  Kappa opioid receptor controls neural stem cell differentiation via a miR‐7a/Pax6 dependent pathway , 2021, Stem cells.

[32]  K. Sangkuhl,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy , 2021, Clinical pharmacology and therapeutics.

[33]  F. Mazzeo,et al.  Data investigation on the performance-enhancing drugs spread in Italy among young athletes: Prevention trough education and the fight against doping in sport , 2021 .

[34]  A. Dmitriev,et al.  LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms , 2020, International journal of molecular sciences.

[35]  E. Oleson,et al.  Buprenorphine is a weak dopamine releaser relative to heroin, but its pretreatment attenuates heroin‐evoked dopamine release in rats , 2020, Neuropsychopharmacology reports.

[36]  Xiaoding Xu,et al.  Non-coding RNAs: the new central dogma of cancer biology , 2020, Science China Life Sciences.

[37]  T. Leroux,et al.  Opioid Use in Athletes: A Systematic Review , 2020, Sports health.

[38]  J. Kennedy,et al.  The pharmacogenetics of opioid treatment for pain management , 2020, Journal of psychopharmacology.

[39]  X. Zhang,et al.  Morphine induces the apoptosis of mouse hippocampal neurons HT-22 through upregulating miR-181-5p. , 2020, European review for medical and pharmacological sciences.

[40]  Ling-Ling Chen The expanding regulatory mechanisms and cellular functions of circular RNAs , 2020, Nature Reviews Molecular Cell Biology.

[41]  Elyssa B. Margolis,et al.  Differential effects of novel kappa opioid receptor antagonists on dopamine neurons using acute brain slice electrophysiology , 2020, bioRxiv.

[42]  Xiaozhou He,et al.  δ-Opioid Receptors, microRNAs, and Neuroinflammation in Cerebral Ischemia/Hypoxia , 2020, Frontiers in Immunology.

[43]  E. Nestler,et al.  Epigenetic Mechanisms of Opioid Addiction , 2020, Biological Psychiatry.

[44]  F. Mazzeo,et al.  From “sliding” to “winding” filaments theory: A narrative review of mechanisms behind skeletal muscle contraction , 2020, Journal of Human Sport and Exercise - 2020 - Spring Conferences of Sports Science.

[45]  R. Lovering,et al.  Non-coding RNA regulatory networks. , 2020, Biochimica et biophysica acta. Gene regulatory mechanisms.

[46]  S. Lisco,et al.  Brain-Derived Extracellular Vesicle microRNA Signatures Associated with In Utero and Postnatal Oxycodone Exposure , 2019, Cells.

[47]  K. Solt,et al.  The rostromedial tegmental nucleus: a key modulator of pain and opioid analgesia. , 2019, Pain.

[48]  Elyssa B. Margolis,et al.  Differential Modulation of Ventral Tegmental Area Circuits by the Nociceptin/Orphanin FQ System , 2019, bioRxiv.

[49]  F. Mazzeo Attitude and practice of substance misuse and dietary supplements to improve performance in sport , 2019, Journal of Substance Use.

[50]  J. Blendy,et al.  Synaptic Regulation by OPRM1 Variants in Reward Neurocircuitry , 2019, The Journal of Neuroscience.

[51]  H. Azizi,et al.  Adolescent Morphine Exposure in Male Rats Alters the Electrophysiological Properties of Locus Coeruleus Neurons of the Male Offspring , 2019, Neuroscience.

[52]  A. Bonci,et al.  Dynorphin/kappa-opioid receptor control of dopamine dynamics: Implications for negative affective states and psychiatric disorders , 2019, Brain Research.

[53]  Mark J. Thomas,et al.  Opioid-Mediated Astrocyte–Neuron Signaling in the Nucleus Accumbens , 2019, Cells.

[54]  F. Slack,et al.  Overexpression of miR-9 in the Nucleus Accumbens Increases Oxycodone Self-Administration , 2019, The international journal of neuropsychopharmacology.

[55]  Shuibo Gao,et al.  Long non-coding RNA MEG3 attends to morphine-mediated autophagy of HT22 cells through modulating ERK pathway , 2019, Pharmaceutical biology.

[56]  Ana Kozomara,et al.  miRBase: from microRNA sequences to function , 2018, Nucleic Acids Res..

[57]  F. Mazzeo,et al.  Use and attitudes toward dietary supplements and drugs amongst Italian elite athletes and its correlation with banned doping substances , 2019, Journal of Human Sport and Exercise - 2019 - Spring Conferences of Sports Science.

[58]  S. Novello,et al.  NOP Receptor Ligands and Parkinson's Disease. , 2019, Handbook of experimental pharmacology.

[59]  L. Kapural,et al.  Influence of postoperative analgesia on systemic inflammatory response and postoperative cognitive dysfunction after femoral fractures surgery: a randomized controlled trial , 2018, Regional Anesthesia & Pain Medicine.

[60]  Jun-Xu Li,et al.  Drug addiction: a curable mental disorder? , 2018, Acta Pharmacologica Sinica.

[61]  E. Boyer,et al.  Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity , 2018, Journal of Medical Toxicology.

[62]  Morphine , 2018, Reactions Weekly.

[63]  F. Mazzeo Anabolic Steroid use in Sports and in Physical Activity: Overview and Analysis , 2018, Sport Mont.

[64]  S. A. Fazeli,et al.  Potential of Extracellular Vesicles in Neurodegenerative Diseases: Diagnostic and Therapeutic Indications , 2018, Journal of Molecular Neuroscience.

[65]  D. W. Odell Epigenetics of pain mediators , 2018, Current opinion in anaesthesiology.

[66]  R. Barkin,et al.  Opioid Therapy in Acute and Chronic Pain , 2018, Journal of clinical pharmacology.

[67]  Michael R Bruchas,et al.  Endogenous and Exogenous Opioids in Pain. , 2018, Annual review of neuroscience.

[68]  J. Berke What does dopamine mean? , 2018, Nature Neuroscience.

[69]  K. Muthusamy,et al.  A Review of the Pedunculopontine Nucleus in Parkinson's Disease , 2018, Front. Aging Neurosci..

[70]  John T. Williams,et al.  The Evolving Understanding of Dopamine Neurons in the Substantia Nigra and Ventral Tegmental Area. , 2018, Annual review of physiology.

[71]  N. Volkow,et al.  Use and Misuse of Opioids in Chronic Pain. , 2018, Annual review of medicine.

[72]  P. Rao,et al.  Potential Role of Extracellular Vesicles in the Pathophysiology of Drug Addiction , 2018, Molecular Neurobiology.

[73]  D. Sanabria,et al.  Analgesics and Sport Performance: Beyond the Pain‐Modulating Effects , 2018, PM & R : the journal of injury, function, and rehabilitation.

[74]  Elyssa B. Margolis,et al.  Two delta opioid receptor subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor , 2017, Neuropharmacology.

[75]  Aniwaa Owusu Obeng,et al.  Review of Opioid Pharmacogenetics and Considerations for Pain Management , 2017, Pharmacotherapy.

[76]  F. Bellivier,et al.  Pharmacoepigenomics of opiates and methadone maintenance treatment: current data and perspectives. , 2017, Pharmacogenomics.

[77]  A. Pipe,et al.  A painful dilemma? Analgesic use in sport and the role of anti-doping , 2017, British Journal of Sports Medicine.

[78]  Costanza Emanueli,et al.  Transcriptional and Post-transcriptional Gene Regulation by Long Non-coding RNA , 2017, Genom. Proteom. Bioinform..

[79]  N. Jeske,et al.  Identification of a signaling cascade that maintains constitutive δ-opioid receptor incompetence in peripheral sensory neurons , 2017, The Journal of Biological Chemistry.

[80]  Tian Liu,et al.  Circles reshaping the RNA world: from waste to treasure , 2017, Molecular Cancer.

[81]  S. Phillips,et al.  Parenteral opioid analgesia: Does it still have a role? , 2017, Best practice & research. Clinical anaesthesiology.

[82]  S. Borgland,et al.  Projection-Target-Defined Effects of Orexin and Dynorphin on VTA Dopamine Neurons. , 2017, Cell reports.

[83]  N. Mercuri,et al.  Functional alterations of the dopaminergic and glutamatergic systems in spontaneous α-synuclein overexpressing rats , 2017, Experimental Neurology.

[84]  Xing Liu,et al.  MiR-218 targets MeCP2 and inhibits heroin seeking behavior , 2017, Scientific Reports.

[85]  N. Mercuri,et al.  On the properties of identified dopaminergic neurons in the mouse substantia nigra and ventral tegmental area , 2017, The European journal of neuroscience.

[86]  J. Paice,et al.  Pain and Opioids in Cancer Care: Benefits, Risks, and Alternatives. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[87]  Anchal Vishnoi,et al.  MiRNA Biogenesis and Regulation of Diseases: An Overview. , 2017, Methods in molecular biology.

[88]  G. Koob Antireward, compulsivity, and addiction: seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction , 2017, Psychopharmacology.

[89]  Yang In Kim,et al.  The contribution of activated peripheral kappa opioid receptors (kORs) in the inflamed knee joint to anti-nociception , 2016, Brain Research.

[90]  A. Akopian,et al.  GRK2 Constitutively Governs Peripheral Delta Opioid Receptor Activity. , 2016, Cell reports.

[91]  Heh-In Im,et al.  Brain Reward Circuits in Morphine Addiction , 2016, Molecules and cells.

[92]  Canan Kuscu,et al.  Biogenesis and Function of Transfer RNA-Related Fragments (tRFs). , 2016, Trends in biochemical sciences.

[93]  M. von Zastrow,et al.  Molecular Pharmacology of δ-Opioid Receptors , 2016, Pharmacological Reviews.

[94]  L. Varriale,et al.  Dietary Supplements Use in Competitive and Non-Competitive Boxer: An Exploratory Study , 2016 .

[95]  M. Monda,et al.  Doping in Italy: An Analysis of its Spread in Ten Years , 2016 .

[96]  M. Kretz,et al.  Non-coding RNAs: Classification, Biology and Functioning. , 2016, Advances in experimental medicine and biology.

[97]  P. Zheng,et al.  Morphine disinhibits glutamatergic input to VTA dopamine neurons and promotes dopamine neuron excitation , 2015, eLife.

[98]  A. Arnsten,et al.  Dopamine’s Actions in Primate Prefrontal Cortex: Challenges for Treating Cognitive Disorders , 2015, Pharmacological Reviews.

[99]  A. Bonci,et al.  Role of Dopamine Neurons in Reward and Aversion: A Synaptic Plasticity Perspective , 2015, Neuron.

[100]  S. Bartlett,et al.  The role of δ‐opioid receptors in learning and memory underlying the development of addiction , 2015, British journal of pharmacology.

[101]  R. Dubner,et al.  Epigenetic regulation of persistent pain. , 2015, Translational research : the journal of laboratory and clinical medicine.

[102]  H. Loh,et al.  Effects of addictive drugs on adult neural stem/progenitor cells , 2015, Cellular and Molecular Life Sciences.

[103]  H. Loh,et al.  Morphine Modulates Mouse Hippocampal Progenitor Cell Lineages by Upregulating miR‐181a Level , 2014, Stem cells.

[104]  Elyssa B. Margolis,et al.  Direct Bidirectional μ-Opioid Control of Midbrain Dopamine Neurons , 2014, The Journal of Neuroscience.

[105]  C. Cahill,et al.  Does the kappa opioid receptor system contribute to pain aversion? , 2014, Front. Pharmacol..

[106]  J. Galligan,et al.  Molecular Physiology of Enteric Opioid Receptors , 2014, American journal of gastroenterology supplements.

[107]  G. Franklin Opioids for chronic noncancer pain , 2014, Neurology.

[108]  S. Hentges,et al.  Separate GABA Afferents to Dopamine Neurons Mediate Acute Action of Opioids, Development of Tolerance, and Expression of Withdrawal , 2014, Neuron.

[109]  S. Lammel,et al.  Reward and aversion in a heterogeneous midbrain dopamine system , 2014, Neuropharmacology.

[110]  K. Befort,et al.  15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse , 2014, Neuropharmacology.

[111]  B. Cox Recent Developments in the Study of Opioid Receptors , 2013, Molecular Pharmacology.

[112]  R. Dannals Positron emission tomography radioligands for the opioid system. , 2013, Journal of labelled compounds & radiopharmaceuticals.

[113]  H. Loh,et al.  Stress-induced epigenetic regulation of κ-opioid receptor gene involves transcription factor c-Myc , 2012, Proceedings of the National Academy of Sciences.

[114]  Borja Mugabure Bujedo,et al.  A review of epidural and intrathecal opioids used in the management of postoperative pain. , 2012, Journal of opioid management.

[115]  M. Pistis,et al.  Inhibitory Inputs from Rostromedial Tegmental Neurons Regulate Spontaneous Activity of Midbrain Dopamine Cells and Their Responses to Drugs of Abuse , 2012, Neuropsychopharmacology.

[116]  Barbara A. Sorg,et al.  Reconsolidation of drug memories , 2012, Neuroscience & Biobehavioral Reviews.

[117]  C. Waddington,et al.  REPRINTS AND REFLECTIONS , 2012 .

[118]  John T. Williams,et al.  Opioid-Sensitive GABA Inputs from Rostromedial Tegmental Nucleus Synapse onto Midbrain Dopamine Neurons , 2011, The Journal of Neuroscience.

[119]  P. Haouzi,et al.  The "other" respiratory effect of opioids: suppression of spontaneous augmented ("sigh") breaths. , 2011, Journal of applied physiology.

[120]  H. Schwarzenbach Impact of physical activity and doping on epigenetic gene regulation. , 2011, Drug testing and analysis.

[121]  G. Calo’,et al.  Nociceptin modulates bronchoconstriction induced by sensory nerve activation in mouse lung. , 2009, American journal of respiratory cell and molecular biology.

[122]  N. Mercuri,et al.  Substantia nigra control of basal ganglia nuclei. , 2009, Journal of neural transmission. Supplementum.

[123]  C. Stevens The evolution of vertebrate opioid receptors. , 2009, Frontiers in bioscience.

[124]  Jennifer M. Mitchell,et al.  δ-Opioid Receptor Expression in the Ventral Tegmental Area Protects Against Elevated Alcohol Consumption , 2008, The Journal of Neuroscience.

[125]  Görel Sundström,et al.  Evolution of vertebrate opioid receptors , 2008, Proceedings of the National Academy of Sciences.

[126]  J. Ballantyne,et al.  Efficacy of Opioids for Chronic Pain: A Review of the Evidence , 2008, The Clinical journal of pain.

[127]  Howard S. Smith,et al.  Variations in opioid responsiveness. , 2008, Pain physician.

[128]  H. Loh,et al.  Epigenetic regulation of kappa opioid receptor gene in neuronal differentiation , 2008, Neuroscience.

[129]  R. Ransohoff,et al.  Multiple roles of chemokine CXCL12 in the central nervous system: A migration from immunology to neurobiology , 2008, Progress in Neurobiology.

[130]  S. Datta,et al.  Opioid pharmacology. , 2008, Pain physician.

[131]  B. Bean The action potential in mammalian central neurons , 2007, Nature Reviews Neuroscience.

[132]  John T. Williams,et al.  Kappa opioid inhibition of somatodendritic dopamine inhibitory postsynaptic currents. , 2007, Journal of neurophysiology.

[133]  John T. Williams,et al.  Properties and Opioid Inhibition of Mesolimbic Dopamine Neurons Vary according to Target Location , 2006, The Journal of Neuroscience.

[134]  Elyssa B. Margolis,et al.  Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[135]  F. Mazzeo,et al.  Naltrexone plus benzodiazepine aids abstinence in opioid-dependent patients. , 2005, Life Science.

[136]  S. Norn,et al.  [History of opium poppy and morphine]. , 2005, Dansk medicinhistorisk arbog.

[137]  D. Grandy,et al.  Vesicular Dopamine Release Elicits an Inhibitory Postsynaptic Current in Midbrain Dopamine Neurons , 2004, Neuron.

[138]  R. Wise Dopamine, learning and motivation , 2004, Nature Reviews Neuroscience.

[139]  Elyssa B. Margolis,et al.  κ-Opioid Agonists Directly Inhibit Midbrain Dopaminergic Neurons , 2003, The Journal of Neuroscience.

[140]  M. Iacobelli,et al.  Use of naltrexone for the treatment of opiate addiction in Campania, Italy: the role of family , 2003 .

[141]  C. Brullo,et al.  2-aryl-3-phenylamino-4,5-dihydro-2h-benz[g]indazoles with analgesic activity. , 2003, Farmaco.

[142]  D. Zochodne,et al.  μ Opioid receptors and analgesia at the site of a peripheral nerve injury , 2003 .

[143]  Steven W. Johnson,et al.  Actions of orphanin FQ/nociceptin on rat ventral tegmental area neurons in vitro , 2002, British journal of pharmacology.

[144]  H. Akil,et al.  Nociceptin/orphanin FQ and opioid receptor‐like receptor mRNA expression in dopamine systems , 2002, The Journal of comparative neurology.

[145]  N. Mercuri,et al.  Intrinsic membrane properties and synaptic inputs regulating the firing activity of the dopamine neurons , 2002, Behavioural Brain Research.

[146]  E. Hoffman,et al.  Associations between MeCP2 mutations, X-chromosome inactivation, and phenotype. , 2002, Mental retardation and developmental disabilities research reviews.

[147]  R. Przewłocki,et al.  Opioids in chronic pain. , 2001, European journal of pharmacology.

[148]  A. Filippelli,et al.  Over-the-counter oral nonsteroidal anti-inflammatory drugs: A pharmacoepidemiologic study in southern Italy , 2001, Advances in therapy.

[149]  J T Williams,et al.  Cellular and synaptic adaptations mediating opioid dependence. , 2001, Physiological reviews.

[150]  Cristina Tassorelli,et al.  Functional changes of the basal ganglia circuitry in Parkinson's disease , 2000, Progress in Neurobiology.

[151]  Peter A. Smith,et al.  Cellular neurophysiological actions of nociceptin/orphanin FQ , 2000, Peptides.

[152]  R. Malenka,et al.  Properties and Plasticity of Excitatory Synapses on Dopaminergic and GABAergic Cells in the Ventral Tegmental Area , 1999, The Journal of Neuroscience.

[153]  S. Watson,et al.  Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat , 1999, The Journal of comparative neurology.

[154]  B Sakmann,et al.  Effect of changes in action potential shape on calcium currents and transmitter release in a calyx-type synapse of the rat auditory brainstem. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[155]  R. Clark,et al.  Midazolam: a review of therapeutic uses and toxicity. , 1997, The Journal of emergency medicine.

[156]  S. Cragg,et al.  Characteristics of electrically evoked somatodendritic dopamine release in substantia nigra and ventral tegmental area in vitro. , 1997, Journal of neurophysiology.

[157]  J. Williams,et al.  A subset of ventral tegmental area neurons is inhibited by dopamine, 5-hydroxytryptamine and opioids , 1997, Neuroscience.

[158]  T. Yaksh,et al.  Peripheral and Spinal Actions of Opioids in the Blockade of the Autonomic Response Evoked by Compression of the Inflamed Knee Joint , 1996, Anesthesiology.

[159]  R. Wise,et al.  The neurobiology of addiction , 2019, Annals of the New York Academy of Sciences.

[160]  Y. Nakajima,et al.  G protein-coupled inward rectifier modulated by dopamine agonists in cultured substantia nigra neurons , 1995, Neuroscience.

[161]  H. Matthes,et al.  The human delta-opioid receptor: genomic organization, cDNA cloning, functional expression, and distribution in human brain. , 1994, Molecular pharmacology.

[162]  G. Bell,et al.  Distribution of κ Opioid Receptor mRNA in Adult Mouse Brain: An in Situ Hybridization Histochemistry Study , 1994, Molecular and Cellular Neuroscience.

[163]  G Vassart,et al.  ORL1, a novel member of the opioid receptor family , 1994, FEBS letters.

[164]  A Goldstein,et al.  Cloning and pharmacological characterization of a rat kappa opioid receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[165]  R. North,et al.  Two types of neurone in the rat ventral tegmental area and their synaptic inputs. , 1992, The Journal of physiology.

[166]  G. Koob Drugs of abuse: anatomy, pharmacology and function of reward pathways. , 1992, Trends in pharmacological sciences.

[167]  J. Tepper,et al.  Stimulus-evoked changes in neostriatal dopamine levels in awake and anesthetized rats as measured by microdialysis , 1991, Brain Research.

[168]  F. Foldes Pain control with intrathecally and peridurally administered opioids and other drugs. , 1991, Anaesthesiologie und Reanimation.

[169]  L. Buéno,et al.  7 Action of opiates on gastrointestinal function , 1988 .

[170]  J. Culpepper-Morgan,et al.  Orally administered kappa as well as mu opiate agonists delay gastrointestinal transit time in the guinea pig. , 1988, Life sciences.

[171]  V. Hruby,et al.  Peptide opioid antagonist separates peripheral and central opioid antitransit effects. , 1987, The Journal of pharmacology and experimental therapeutics.

[172]  N. Mercuri,et al.  Dopamine acts on D2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta. , 1987, The Journal of physiology.

[173]  J Sawynok,et al.  The therapeutic use of heroin: a review of the pharmacological literature. , 1986, Canadian journal of physiology and pharmacology.

[174]  J. Fallon,et al.  Dynorphin-containing pathways in the substantia nigra and ventral tegmentum: A double labeling study using combined immunofluorescence and retrograde tracing , 1985, Neuropeptides.

[175]  M. Palkovits,et al.  Distribution of immunoreactive dynorphin in the central nervous system of the rat , 1983, Brain Research.

[176]  T. Hökfelt,et al.  Immunohistochemical evidence for a dynorphin immunoreactive striato-nigral pathway. , 1982, European journal of pharmacology.

[177]  A. Herz,et al.  Immunoreactive dynorphin in human brain and pituitary , 1982, Brain Research.

[178]  A. Sawa,et al.  Evidence that dynorphin-(1–13) acts as an agonist on opioid κ-receptors , 1982 .

[179]  C. Chavkin,et al.  Dynorphin is a specific endogenous ligand of the kappa opioid receptor. , 1982, Science.

[180]  Robert S. Lockhart,et al.  Learning and Motivation , 1981 .

[181]  L. Hood,et al.  Dynorphin-(1-13), an extraordinarily potent opioid peptide. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[182]  K. Kangawa,et al.  alpha-Neo-endorphin : a "big" Leu-enkephalin with potent opiate activity from porcine hypothalami. , 1979, Biochemical and biophysical research communications.

[183]  T. Jessell,et al.  Release of dopamine from dendrites in rat substantia nigra , 1976, Nature.

[184]  O. Lindvall,et al.  Dopamine in dendrites of substantia nigra neurons: suggestions for a role in dendritic terminals , 1975, Brain Research.